Holen Sie sich die Stockscreener-App
10.22
1.16%
-0.12
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NVAX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$10.34
Offen:
$10.5
24-Stunden-Volumen:
5.12M
Relative Volume:
1.20
Marktkapitalisierung:
$1.69B
Einnahmen:
$596.34M
Nettoeinkommen (Verlust:
$-87.84M
KGV:
-17.10
EPS:
-0.5975
Netto-Cashflow:
$-97.62M
1W Leistung:
+10.37%
1M Leistung:
+33.42%
6M Leistung:
+3.34%
1J Leistung:
+31.19%
1-Tages-Spanne:
$10.04
$10.75
1-Wochen-Bereich:
$9.09
$10.75
52-Wochen-Spanne:
$6.20
$11.97
Novavax Inc Stock (NVAX) Company Profile
Firmenname
Novavax Inc
Sektor
Branche
Telefon
240-268-2000
Adresse
21 FIRSTFIELD RD, GAITHERSBURG, MD
Compare NVAX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
10.22 | 1.39B | 596.34M | -87.84M | -97.62M | -0.5975 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-08-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-08-20 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-06-17 | Eingeleitet | Citigroup | Sell |
| 2025-02-28 | Eingeleitet | BTIG Research | Buy |
| 2024-07-30 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-05-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-05-10 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-08-09 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | Bestätigt | B. Riley Securities | Buy |
| 2022-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-02 | Eingeleitet | Jefferies | Hold |
| 2022-09-22 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-20 | Eingeleitet | BofA Securities | Underperform |
| 2022-02-23 | Bestätigt | B. Riley Securities | Buy |
| 2022-02-22 | Fortgesetzt | Jefferies | Buy |
| 2022-01-21 | Eingeleitet | Cowen | Outperform |
| 2021-05-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-05 | Herabstufung | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | Bestätigt | B. Riley FBR | Buy |
| 2020-06-29 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-05-28 | Bestätigt | B. Riley FBR | Buy |
| 2020-05-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-27 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-08-14 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-28 | Herabstufung | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-12-11 | Eingeleitet | Oppenheimer | Outperform |
| 2018-11-26 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2018-03-29 | Hochstufung | Seaport Global Securities | Neutral → Buy |
Alle ansehen
Novavax Inc Aktie (NVAX) Neueste Nachrichten
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
NVAX Stock Alert: Biotechs Hit Post-Pandemic High on mRNA Cancer Breakthrough - Barchart.com
Novavax Stock Hits Over 1-Year High: Is Sanofi’s Flu-COVID Shot The Post-Pandemic Growth Driver? - Stocktwits
Novavax Q4 Earnings Preview: Wall Street Expects Wider Losses Amid Diversification Efforts - Stocktwits
Novavax Inc. Stock Rallies 10.8%, Outperforms Peers - webull.com
Recursion, Novavax, Crispr Therapeutics Stocks Slip Premarket After Cancer Therapy RallyRecursion Phar - Benzinga
Novavax (NVAX) Is Up 10.4% After Steep Q2 Revenue Drop And Swing To Net Loss – Has The Bull Case Changed? - simplywall.st
Novavax (NVAX) Shares Skyrocket, What You Need To Know - Yahoo Finance
Novavax Stock Moves Higher Wednesday: What's Driving the Action? - TradingView
Gold Mining, Drug Stocks Breaking Out Today - Schaeffer's Investment Research
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Novavax (NVAX) Slips to $8.05 as Biotech Stock Tests Key Support ZoneContinuation Pattern Picks - vinanet.vn
Novavax, Inc. (NASDAQ:NVAX) Given Consensus Rating of "Hold" by Analysts - MarketBeat
(NVAX) Volatility Zones as Tactical Triggers - Stock Traders Daily
NVAX Stock Is Rising Even After A Revenue Collapse – Here’s The Catch - Stocktwits
NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash - Stocktwits
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue - Stocktwits
How Novavax’s (NVAX) Earnings Slide and New Share Shelf Will Impact Investors - webull.com
Bank of America Corp DE Cuts Stock Holdings in Novavax, Inc. $NVAX - MarketBeat
Novavax, Inc. (NVAX) Stock Analysis: Growth Potential Amidst A 77% Upside - DirectorsTalk Interviews
Novavax, Inc. (NVAX) Options Chain - Yahoo! Finance Canada
Novavax (NASDAQ:NVAX) Lowered to Hold Rating by Zacks Research - MarketBeat
Novavax (NVAX) Gets a Sell from Bank of America Securities - The Globe and Mail
Renaissance Technologies LLC Invests $4.05 Million in Novavax, Inc. $NVAX - MarketBeat
Novavax (NVAX) Stock Faces Revenue Slump As Losses Deepen - Sahm
NVAX Q2 Earnings & Sales Beat Estimates, '26 Sales Outlook Raised - Yahoo Finance
State Street Corporation (NYSE: STT) discloses 7.1% ownership of Novavax - Stock Titan
Novavax, Inc. Stock 12‑Month Price Target Cut to $13.75, Implies 78% Upside - TradingView
Novavax Q2 2026 slides: partnership pivot drives revenue beat By Investing.com - Investing.com Nigeria
NVAX SWOT Analysis: Financial Challenges and Opportunities Revea - GuruFocus
Novavax Q2 Earnings Call Highlights - MarketBeat
Novavax (NASDAQ:NVAX) Posts Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
NVAX Looks 107.0% Overvalued on GF Value™ - GuruFocus
Novavax Inc (NVAX) (Q2 2026) Earnings Call Highlights: Matrix-M - GuruFocus
Novavax Inc (NVAX) (Q2 2026) Earnings Call Highlights: Matrix-M Momentum Drives Revenue ... - Yahoo Finance
Novavax Q2 2026 Earnings Call Transcript - MarketBeat
Novavax, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:NVAX) 2026-08-06 - Seeking Alpha
NVAX Stock Holds Steady As Novavax Lifts Revenue Outlook On Licensing Pivot — Retail Eyes Buyout, More Partnership Deals - Yahoo Finance
Novavax raises annual revenue forecast as licensing bets offset weak vaccine demand - kfgo.com
Novavax Q2 2026 slides: partnership pivot drives revenue beat - Investing.com
Novavax Raises 2026 Revenue Outlook After Q2 Earnings Beat - citybiz
NVAX: Q2 2026 revenue reached $57M, with strong Matrix-M growth and major partnership milestones ahead - TradingView
Earnings call transcript: Novavax beats Q2 2026 estimates, lifts revenue outlook - Investing.com
Is Novavax Inc (NVAX) Under Pressure After Q2 Earnings Miss? EPS - GuruFocus
Novavax, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Novavax tops forecasts and raises revenue outlook as Sanofi collaboration progresses - Yahoo Finance
Novavax (NVAX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Are Medical Stocks Lagging Novavax (NVAX) This Year? - Yahoo Finance
NVAX: Q2 2026 product sales rose 76% YoY, but total revenue fell sharply as milestone payments declined - TradingView
Novavax, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Finanzdaten der Novavax Inc-Aktie (NVAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):